

Curriculum Vitae

Stephen G. Williams
Kaiser Permanente Riverside Medical Center
Dept. of Urology
10800 Magnolia Ave
Riverside, CA 92505
951-353-4412
stephen.g.williams@kp.org

Education and Post-Graduate Training

9/83 - 6/87	Princeton University, B.A. Psychology
7/89 - 6/93	Loyola University - Chicago, Stritch School of Medicine, M.D.
6/93 - 6/95	Intern/Resident, Department of Surgery, University of California – Davis, Sacramento, CA
7/95 – 6/98	Resident, Department of Urology, University of California-Davis, Sacramento, CA
7/98 – 6/99	Chief Resident, Department of Urology, University of California-Davis, Sacramento, CA
7/99 – 6/01	Fellow, Urologic Oncology, University of Southern California/ Los Angeles County Hospital, Norris Comprehensive Cancer Center, Los Angeles, CA

Academic Appointments

7/99 – 6/01	Clinical Instructor, Department of Urology University of Southern California School of Medicine
8/01 – 8/02	Assistant Clinical Professor of Surgery, Division of Urology University of California, San Diego, San Diego, CA
11/03-present	Academic Faculty member, Center for Medical Education and the Department of Urology, Kaiser Permanente – Los Angeles Medical Center
6/06 – 12/2009	Assistant Chief, Department of Urology – Kaiser Permanente Los Angeles Medical Center
12/07 – 10/2010	Urology Residency Program Director, Kaiser Permanente Los Angeles Medical Center

2/2014 – Present Chief, Dept of Urology, Kaiser Riverside Medical Center
7/2016 – Present Director, Urologic Oncology, Southern California Permanente Medical group

Licensure State of California Medical Board, License #G079866

Awards/Honors

1997 1st Prize Northern California Residents' Competition. *Complex Urologic Malignancy*
1998 3rd prize, Northern California Residents' Competition. *Differences In Gene Expression In Muscle-Invasive Bladder Cancer: A Comparison of Italian and American Patients.*
1999 2nd prize, Northern California Residents' Competition. *Artificial urinary sphincter implantation in the irradiated patient: safety, efficacy and satisfaction.*
1999 Pfizer Scholar in Urology
2004 1st Prize Poster Session: Western Section AUA, San Diego: *Determining Dosing Interval For LH-RH Agonists Based On Serum Testosterone Level: A preliminary Assessment.*
2013 Physician of The Year- Kaiser Permanente Riverside Medical Center

Appointments

1. Administrative Cancer Committee, Los Angeles Medical Center: 2005 – 2010
2. Chairman, Kaiser Permanente National Urology Symposium: 2007 – 2010
3. Kaiser Permanente National Urology Symposium Committee, Jan., 2002 - present
4. Residency Program Director, Dept of Urology: November, 2007 – Sept., 2010.
5. SROCTAP (Surgical and Radiation Oncology Clinical Trials Access Program), Founding Committee member, 2007-present
6. Reviewer – Annals of Surgical Oncology: 2010 – 2012
7. LAMC Emerging Leaders Cohort: Aug., 2008 – June., 2009
8. SCPMG Robotic Surgery Core Committee 2008-present
9. Administrative Cancer Committee, Riverside Medical Center: July, 2011 – present
10. Co-founder, Regional GU Multidisciplinary Clinic, SCPMG: 2011-present
11. Director, SCPMG Robotic Cystectomy Program: Sept., 2012 – Present
12. Reviewer, Urology Practice: 2014-present
13. Co-Chair, Riverside Medical Center Administrative Cancer Committee, 2014-present
14. Chief, Dept of Urology, Kaiser Riverside Medical Center: February, 2014 – present
15. Director, Riverside Comprehensive Cancer Program, 2015- present

Current Regional/Professional Committees

1. American Urological Association (AUA)
2. Society of Urologic Oncology
3. AUA- Western Section
4. Riverside County Medical Association
5. California Medical Association
6. California Urological Association

Clinical Trials

1. KPSC Co-investigator: "Use of Fresh Prostate Cancer Tissue to Develop Tumor Specific Monoclonal Antibodies" [with Raven Biotechnology, Inc.], 2004-2012, (Study completed)
2. **KPSC Principal Investigator:** *A Multicenter, Randomized Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer.* 2008-2011 (study completed)

Presentations/Grand Rounds – Kaiser Permanente

1. Update on the Diagnosis and Treatment of Testicular Cancer – Dept. of Surgery Grand Rounds, April, 2003
2. Update on Urinary Diversion – Cancer Committee Grand Rounds, July 15, 2003
3. Erectile Dysfunction Following Treatment for Urologic Cancers, Cancer Committee Grand Rounds, Sept. 21, 2004
4. Metabolic Consequences of Urinary Diversion - Nephrology Grand Rounds, March 23, 2005
5. Update on Bladder cancer - 2006 – General Surgery Grand Rounds, Nov. 7, 2006
6. Urinary Tract Reconstruction – General Surgery Grand Rounds, March 6, 2007
7. Current Paradigms in the Treatment of Invasive Bladder cancer – Radiation Oncology Grand Rounds, March 11, 2008
8. *Robotic Surgery - The future of surgical oncology?* SCPMG Radiation Oncology Annual Symposium, January 8-9, 2010
9. Update on Urinary Diversion and Metabolic Consequences, Nephrology Grand Rounds, January 12, 2010

Abstracts/Papers Presented

1. Percutaneous electrovaporization of upper tract transitional cell carcinoma. Western Section AUA, San Diego, CA. July 28 – August 1, 1996.
2. The burnt-out bladder: a poorly recognized condition in the elderly female patient. Western Section AUA, San Diego, CA. July 28 – August 1, 1996.
3. Stapled continent urinary reconstruction: reliable, quick and cost-effective. Western Section AUA, Salt Lake City, UT Sept. 14-17, 1997.

4. Is prior radiation therapy a contraindication to artificial sphincter implantation? Western Section AUA, Salt Lake City, UT Sept. 14-17, 1997.
5. Molecular differences in muscle-invasive bladder cancer: an evaluation of two patient populations. Western Section AUA, Kona, HI October 25-30, 1998.
6. Endopyelotomy for treatment of ureteropelvic junction obstruction caused by torsion of a renal allograft. Western Section AUA, Kona, HI October 25-30, 1998.
7. Urine levels of vascular endothelial factor are associated with survival in patients with transitional cell carcinoma of the bladder. Annual AUA Meeting, Atlanta, GA April 29-May 4, 2000.
8. Expression of vascular endothelial growth factor expression and thrombospondin-1 in bladder cancer. Annual AUA Meeting, Anaheim, CA June 2-7, 2001.
9. Ethnic Variability in Prostate Cancer at Kaiser Permanente, Western Section AUA, Lake Las Vegas, November 2-6, 2003.
10. Determining Dosing Interval For LH-RH Agonists Based On Serum Testosterone Level: A preliminary Assessment, Western Section AUA, San Diego, August 22-26, 2004.
11. Determining Dosing Interval for LH-RH Agonists Based On Serum Testosterone Levels: A Prospective Study, AUA – San Antonio, May 21-26, 2005
12. Recovery of Erectile Function Following Radical Prostatectomy: Identifying Prognostic Indicators, Western Section AUA, Maui, October 22-26, 2006
13. A cost analysis of Testosterone-Based Hormonal Therapy using LH-RH agonists. Western Section AUA, Maui, October 22-26, 2006
14. Salvage Cryotherapy of the Prostate: A Prospective Study of Quality of Life Indicators. Western Section AUA, Scottsdale. Oct. 28-Nov. 1, 2007
15. Treatment Failure is Associated with Different Dosing Regimens of LHRH agonist Therapy for Prostate Cancer, Society of Urologic Oncology, Bethesda, MD, Dec. 4-5, 2008
16. Pre-treatment Testosterone Level Is Associated with Androgen Resistance in Primary LH-RH Agonist Therapy for Prostate Cancer, AUA - Chicago, April 25-29, 2009
17. African American Men Have Lower Rate of Early Androgen Resistance on Primary LHRH Agonist Therapy for Prostate Cancer, AUA – Chicago, April 25-29, 2009
18. Early Androgen Resistance is Associated with Different Dosing Regimens of LHRH agonist Therapy for Prostate Cancer, AUA – Chicago, April 25-29, 2009
19. Time to Oncologic Proficiency in Robotic Radical Prostatectomy: Successfully Reducing the Learning Curve in a Multi-surgeon Program, AUA – Washington DC, May 14-19, 2011

Publications

1. **Williams, S.G.**, McVicar, J.P., and Low, R.K.: Endopyelotomy For Treatment of Ureteropelvic Junction Obstruction Caused By Torsion Of A Renal Allograft. *J. Urology*, 161: 1560-61, 1999.
2. Edelman, MJ, Meyers, FJ, Miller, TR, **Williams SG**, Gandour-Edwards, R., deVere White, RW: Phase I/II study of Paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. *Urology*, 55 (4): 521-5, 2000.
3. Walsh, I., **Williams, SG.**, and Stone, AR. Artificial urinary sphincter implantation in the irradiated patient: safety, efficacy and satisfaction. *BJU International* , 85(5): 32, 2000.
4. **Williams, S.G.**, Gandour-Edwards, R., Deitch, A.D., Toscano, S., Fan, J.J., Sternberg, C.N., Rossetti, A., Pansadoro, V., and deVere White, R.W.: Differences In Gene Expression In Muscle-Invasive Bladder Cancer: A Comparison of Italian and American Patients. *European Urology* 39(4):430-7, 2001.
5. **Williams, S.G.**, Buscarini, M., and Stein, J.P.: Molecular Markers for Diagnosis, Staging, and Prognosis of Bladder Cancer. *Oncology* 15(11): 1461-84, 2001.
6. **Williams, SG** and Stein, J.P.: Molecular Pathways in Bladder Cancer. *Urological Research*. 32 (6): 373-85, December, 2004.
7. Pathak, AS, Pacificar, J, Shapiro, CE and **Williams, SG**. Determining Dosing Intervals For Luteinizing Hormone-Releasing Hormone Agonists Based on Serum Testosterone Levels: A Prospective Study. *Journal of Urology*. 177 (6):2132-2135, 2007.
8. Alan A. Nisbet, M.D., Jocelyn M. Rieder, M.D., Viet Q. Tran, M.D., **Stephen G. Williams, M.D.**, and Gary W. Chien: Decision Tree for Laparoscopic Partial Nephrectomy versus Laparoscopic Renal Cryoablation for Small Renal Masses. *Journal of Endourology*, 23 (3): March, 2009.
9. Kwon EO, Bautista TC, Blumberg JM, Jung H, Tamaddon K, Aboseif SR, **Williams SG**, Chien GW. Rapid Implementation of a robot-assisted Prostatectomy program in a large health maintenance program. *J Endourol*. 2010 Mar;24(3):461-5.
10. Kwon EO, Bautista TC, Jung H, Goharderakhshan RZ, **Williams SG**, Chien GW. Impact of Robotic Training on surgical and pathologic outcomes during robot-assisted laparoscopic radical prostatectomy. *Urology*. 2010 Aug;76(2):363-8.
11. Blumberg, JM, Kwon, EO, Cheetham,C, Niu,F, Shapiro, C, Loo, RK, **Williams, SG**, Chien,GW. Early Development of Castrate Resistance Varies with Different Dosing Regimens of Leutinizing Hormone Releasing Hormone Agonist in Primary Hormonal Therapy for Prostate Cancer. *Urology* 2011; 77:412

12. SOPHIA RAHMAN, M.D., HARRY COSMATOS, M.D., GIATRI DAVE, M.D., **STEPHEN WILLIAMS, M.D.**, AND MICHAEL TOME, M.D. Predicting Pelvic Lymph Node Involvement in Current Era Prostate Cancer. *The International Journal of Radiation Oncology, Biology, and Physics*. April, 2011: 1-5.
13. Sassani P, Blumberg J, Cheetham TC, Niu F, **Williams SG**, and Chien G. Black Men Have Lower Rates Than White Men of Biochemical Failure with Primary Androgen-Deprivation Therapy. *The Permanente Journal*. Vol. 15, No., 3, 2011, pp 4-7.
14. Chao C, Jacobsen SJ, Xu L, Wallner L, Porter K, **Williams SG**. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy in a managed care organization. *BJU International*, September, 2012.
15. Brian Kim, MD, Allen Chang, MD, Jennifer Kaswick, BS, Armen Derbogossians, MD, Howard Jung, MD, Jeff Slezak, MS, Melanie Wuerstle, MD, **Stephen G. Williams, MD**, Gary W. Chien, MD. Achieving proficiency with robot-assisted radical prostatectomy: Laparoscopic-trained versus robotics-trained surgeons. *Canadian Urologic Association Journal*, Vol. 7, pp. E711-715., 2013
16. **S. Williams**, Editorial Comment: Process Improvements Positively Impact the Use of Intravesical Mitomycin C after Transurethral Resection of Nonmuscle Invasive Bladder Cancer, *Urology Practice*, Vol. 2, 297, Nov., 2015.

Current Research Interests

1. **Role of Lymphadenectomy in Robotic Radical Prostatectomy: Frequency and Quality during the Learning Curve**
2. **Testosterone-Based LHRH dosing in men with prostate cancer**
3. **Salvage Cryotherapy for Recurrent Prostate Cancer: efficacy and quality of life outcomes**
4. **Practice Patterns for Use of Intravesical Therapy for Superficial Bladder CA**
5. **Long Term Follow up of Radical cystectomy cohort, KP 2003-2014**